Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid leukemia (CML), the majority of patients still require lifelong tyrosine kinase inhibitor (TKI) therapy. This is primarily caused by resisting leukemic stem cells (LSCs), which preven...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Leukemia
मुख्य लेखकों: Parting, Oliver, Langer, Samantha, Kuepper, Maja Kim, Wessling, Caroline, Li, Shaoguang, Braunschweig, Till, Chatain, Nicolas, Maié, Tiago, Costa, Ivan G., Crysandt, Martina, Huber, Michael, Brümmendorf, Tim H., Koschmieder, Steffen, Schemionek, Mirle
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Publishing Group UK 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515845/
https://ncbi.nlm.nih.gov/pubmed/32684632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0977-8
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन